Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”
Cancer Network,
ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma.
Real-World Data Showcase Favorable Outcomes and Less Toxicity With Axi-Cel in Large B-Cell Lymphoma
OncLive,
The real-world utilization of axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated favorable outcomes and less frequent…
Axicabtagene Ciloleucel Approved in Japan for Relapsed/Refractory LBCL
OncLive,
The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel (Yescarta; axi-cel…